596 related articles for article (PubMed ID: 29273397)
1. Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.
Harrison IF; Smith AD; Dexter DT
Neurosci Lett; 2018 Feb; 666():48-57. PubMed ID: 29273397
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
3. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
Harrison IF; Powell NM; Dexter DT
J Neurochem; 2019 Jan; 148(1):136-156. PubMed ID: 30269333
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Histone Acetylation by Autophagy in Parkinson Disease.
Park G; Tan J; Garcia G; Kang Y; Salvesen G; Zhang Z
J Biol Chem; 2016 Feb; 291(7):3531-40. PubMed ID: 26699403
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
8. Manganese chloride induces histone acetylation changes in neuronal cells: Its role in manganese-induced damage.
Guo Z; Zhang Z; Wang Q; Zhang J; Wang L; Zhang Q; Li H; Wu S
Neurotoxicology; 2018 Mar; 65():255-263. PubMed ID: 29155171
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease.
de Oliveira RM; Vicente Miranda H; Francelle L; Pinho R; Szegö ÉM; Martinho R; Munari F; Lázaro DF; Moniot S; Guerreiro P; Fonseca-Ornelas L; Marijanovic Z; Antas P; Gerhardt E; Enguita FJ; Fauvet B; Penque D; Pais TF; Tong Q; Becker S; Kügler S; Lashuel HA; Steegborn C; Zweckstetter M; Outeiro TF
PLoS Biol; 2017 Mar; 15(3):e2000374. PubMed ID: 28257421
[TBL] [Abstract][Full Text] [Related]
10. Histone hyperacetylation up-regulates protein kinase Cδ in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease.
Jin H; Kanthasamy A; Harischandra DS; Kondru N; Ghosh A; Panicker N; Anantharam V; Rana A; Kanthasamy AG
J Biol Chem; 2014 Dec; 289(50):34743-67. PubMed ID: 25342743
[TBL] [Abstract][Full Text] [Related]
11. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
Harrison IF; Crum WR; Vernon AC; Dexter DT
Br J Pharmacol; 2015 Aug; 172(16):4200-15. PubMed ID: 26040297
[TBL] [Abstract][Full Text] [Related]
12. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
Outeiro TF; Kontopoulos E; Altmann SM; Kufareva I; Strathearn KE; Amore AM; Volk CB; Maxwell MM; Rochet JC; McLean PJ; Young AB; Abagyan R; Feany MB; Hyman BT; Kazantsev AG
Science; 2007 Jul; 317(5837):516-9. PubMed ID: 17588900
[TBL] [Abstract][Full Text] [Related]
13. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
[TBL] [Abstract][Full Text] [Related]
14. CIITA expression is regulated by histone deacetylase enzymes and has a role in α-synuclein pre-formed fibril-induced antigen presentation in murine microglial cell line.
Günaydın C; Çelik ZB; Bilge SS
Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):447-455. PubMed ID: 35291899
[TBL] [Abstract][Full Text] [Related]
15. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
16. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
[TBL] [Abstract][Full Text] [Related]
17. Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration.
Song C; Kanthasamy A; Jin H; Anantharam V; Kanthasamy AG
Neurotoxicology; 2011 Oct; 32(5):586-95. PubMed ID: 21777615
[TBL] [Abstract][Full Text] [Related]
18. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
[TBL] [Abstract][Full Text] [Related]
19. Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
Mazzocchi M; Goulding SR; Morales-Prieto N; Foley T; Collins LM; Sullivan AM; O'Keeffe GW
Brain Behav Immun; 2022 May; 102():151-160. PubMed ID: 35217173
[TBL] [Abstract][Full Text] [Related]
20. LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.
Mazzocchi M; Goulding SR; Wyatt SL; Collins LM; Sullivan AM; O'Keeffe GW
Mol Cell Neurosci; 2021 Sep; 115():103642. PubMed ID: 34119632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
